🇺🇸 FDA
Pipeline program

LV305

IMDZ-04-1702

Phase 3 mab terminated

Quick answer

LV305 for Synovial Sarcoma is a Phase 3 program (mab) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Synovial Sarcoma
Phase
Phase 3
Modality
mab
Status
terminated

Clinical trials